Suppr超能文献

0.4毫克地塞米松缓释眼内植入剂用于眼科手术后眼内炎症和疼痛的治疗:设计、研发及治疗地位

Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy.

作者信息

Brooks Cassandra C, Jabbehdari Sayena, Gupta Preeya K

机构信息

Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA.

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.

出版信息

Clin Ophthalmol. 2020 Jan 13;14:89-94. doi: 10.2147/OPTH.S238756. eCollection 2020.

Abstract

Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain.

摘要

炎症和疼痛是眼部手术后常见的两种症状。皮质类固醇作为控制术后炎症和疼痛的核心治疗方法被广泛应用。患者对术后眼药水治疗方案的依从性差、局部眼药水的生物利用度有限以及许多此类眼药水所用防腐剂的负面影响,使得新型疗法在治疗术后疼痛和炎症方面具有充分的理由。这篇文献综述将聚焦于泪小管内缓释地塞米松(Dextenza,美国马萨诸塞州贝德福德市的Ocular Therapeutix公司生产)在眼部炎症和疼痛管理中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae99/6968807/72a215218d28/OPTH-14-89-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验